当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Nivolumab in paediatric cancer: children are not little adults.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-03-16 , DOI: 10.1016/s1470-2045(20)30086-3 Jaume Mora 1 , Shakeel Modak 2
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-03-16 , DOI: 10.1016/s1470-2045(20)30086-3 Jaume Mora 1 , Shakeel Modak 2
Affiliation
|
The anti-PD-1 monoclonal antibody nivolumab is one of 33 US Food and Drug Administration approved antibodies or conjugates for the treatment of cancer. Nivolumab is approved in adults with high microsatellite instability or mismatch repair-deficient metastatic colon cancer, and as second-line therapy in advanced melanoma, several carcinomas, and relapsed Hodgkin lymphoma. With such a broad profile of anticancer activity, testing its activity in paediatric malignancies seems reasonable. In doing so, there is a potential benefit for all stakeholders involved in novel anticancer drug development for children. The pharmaceutical industry is incentivised to test such drugs in children and is encouraged by potential regulatory and economic benefits. Paediatric oncologists and patients welcome new options for recurrent and refractory cancer because they have fewer anticancer drugs available than do adult patients. However, this approach to clinical trials that tests drugs from adult oncology yields results that are mostly negative. And they are negative because we continue to forget that paediatric tumours are disparate from those in adults.
中文翻译：
尼武单抗治疗小儿癌症：儿童不是小成年人。
抗PD-1单克隆抗体nivolumab是美国食品药品监督管理局批准的33种用于治疗癌症的抗体或结合物之一。Nivolumab被批准用于具有高微卫星不稳定性或错配修复缺陷的转移性结肠癌的成人，并作为晚期黑色素瘤，几种癌和复发性霍奇金淋巴瘤的二线治疗。鉴于抗癌活性如此广泛，测试其在儿科恶性肿瘤中的活性似乎是合理的。这样，参与儿童新型抗癌药物开发的所有利益相关者都有潜在的利益。制药行业受到激励在儿童中测试此类药物，并受到潜在监管和经济利益的鼓舞。小儿肿瘤学家和患者欢迎复发性和难治性癌症的新选择，因为它们比成人患者拥有更少的抗癌药物。但是，这种从成人肿瘤学中测试药物的临床试验方法得出的结果大多是负面的。它们是负面的，因为我们继续忘记小儿肿瘤与成年人的肿瘤截然不同。
更新日期：2020-03-31
中文翻译：
尼武单抗治疗小儿癌症：儿童不是小成年人。
抗PD-1单克隆抗体nivolumab是美国食品药品监督管理局批准的33种用于治疗癌症的抗体或结合物之一。Nivolumab被批准用于具有高微卫星不稳定性或错配修复缺陷的转移性结肠癌的成人，并作为晚期黑色素瘤，几种癌和复发性霍奇金淋巴瘤的二线治疗。鉴于抗癌活性如此广泛，测试其在儿科恶性肿瘤中的活性似乎是合理的。这样，参与儿童新型抗癌药物开发的所有利益相关者都有潜在的利益。制药行业受到激励在儿童中测试此类药物，并受到潜在监管和经济利益的鼓舞。小儿肿瘤学家和患者欢迎复发性和难治性癌症的新选择，因为它们比成人患者拥有更少的抗癌药物。但是，这种从成人肿瘤学中测试药物的临床试验方法得出的结果大多是负面的。它们是负面的，因为我们继续忘记小儿肿瘤与成年人的肿瘤截然不同。
京公网安备 11010802027423号